Form 4: Jazz Pharmaceuticals Executive Renee D. Gala Reports Tax-Related Share Disposal

Renee D. Gala, President & COO of Jazz Pharmaceuticals, disposed of 1,736 ordinary shares on April 5, 2024, to cover tax obligations arising from vesting restricted stock units.

Summary

• On April 5, 2024, Renee D. Gala, the President & COO of Jazz Pharmaceuticals, disposed of 1,736 ordinary shares.
• The shares were withheld to satisfy tax obligations related to the vesting of previously granted restricted stock units.
• The transaction was executed at a price of $115.21 per share.
• Following the transaction, Gala directly owns 55,357 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It doesn't indicate any significant positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction related to executive compensation and tax obligations. It is common for company executives to sell shares to cover taxes when restricted stock units vest. This type of transaction is normal and doesn't necessarily reflect a change in the executive's confidence in the company.

Comparison to Industry Standards

• Similar transactions are common among executives at publicly traded companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) when dealing with vesting of stock options or restricted stock units.
• These companies' executives often report similar Form 4 filings related to tax obligations.
• The amount of shares disposed of is relatively small compared to the total holdings, which is typical for these types of transactions.

Stakeholder Impact

• The transaction has minimal impact on shareholders as it is a routine sale to cover tax obligations.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates